Dr. Bill Lundberg has left his role as chief scientific officer of CRISPR Therapeutics but will lead the company's scientific advisory board.
The SensAheart device was developed in Israel to detect heart attacks experienced by patients as recently as an hour prior using blood samples taken by finger prick, providing results within about five minutes. The device, approximately the size of a USB stick, is available in Israel and Europe, and its inventor, Novamed founder and CEO Emil Katz, is working on bringing the device to the US market.
Swedish researchers found that rising levels of cardiac troponin measured by a high-sensitivity assay were associated with increased adjusted hazard ratios for all-cause, cardiovascular- and noncardiovascular-related mortality, heart failure and myocardial infarction, according to a study. During heart failure, a small but continuous release of cTnT from the myocardium is an indication that "chronic troponin release may be mediated by functional and structural heart diseases rather than by ischemic heart disease," researchers wrote.
The Canadian Treatment Action Council has begun a campaign to increase access to hepatitis C treatment with the goal of eliminating hepatitis C viral infections in Canada. "Canada lacks a stand-alone hepatitis action plan, and a clear commitment to the well-being and quality of life of people living with HCV. Strategies at the provincial, territorial, and federal levels are needed that set measurable goals, and are in line with WHO goals and measures of success," wrote Shelina Karmali, executive director of the council, and colleagues.
ContraVir Pharmaceuticals reported that its hepatitis B candidate tenofovir exalidex, or TXL, was found to be safe and well tolerated in treating patients with severe renal impairment and with normal kidney function, according to an early-stage study.
GlycoMimetics and the Haemato Oncology Foundation for Adults in the Netherlands will initiate a trial later this year to evaluate the efficacy of its experimental drug GMI-1271 in combination with the chemo agent decitabine as a treatment for newly diagnosed adult patients with acute myeloid leukemia and myelodysplastic syndrome who are intolerant to intensive chemotherapy. The primary goals of the 140-subject study consist of remission rate, disease-free survival and overall survival.
Sanofi said it will halt development of a half-dozen drug programs that include a Phase II study for isatuximab to treat acute lymphoblastic leukemia and GLD52 to treat relapsing multiple sclerosis. The company didn't say why the programs were being discontinued.
Brazilian health officials have confirmed an additional 140 cases of yellow fever in the country, bringing the total since July to 353. An additional 17 deaths were reported, bringing that total to 98.
Sophia Genetics' sequencing-based molecular diagnostics test for mutations related to myeloid and lymphoid leukemia has been granted the CE-IVD mark by European regulators.
A statistical brief from the Healthcare Cost and Utilization Project found a significant increase in hospitalization for patients with hepatitis C, notably among baby boomers and people with substance abuse and mental health disorders. Between 2005 and 2014, the rate of hospitalization for baby boomers with hepatitis C rose 67.3%.